Lixte Book Value Per Share from 2010 to 2024

LIXT Stock

USD 2.23 0.06 2.76%

Lixte Biotechnology Book Value Per Share yearly trend continues to be comparatively stable with very little volatility. Book Value Per Share is likely to outpace its year average in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Lixte Biotechnology Holdings according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

2.08931067

Current Value

2.27

Quarterly Volatility

8.13808488

Credit Downgrade

Yuan Drop

Covid

Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 17 K, Other Operating Expenses of 2.7 M or EBITDA of 3.4 K, as well as many indicators such as Price To Sales Ratio of 9.35, Dividend Yield of 0.0011 or PTB Ratio of 1.18. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.

Check out the analysis of Lixte Biotechnology Correlation against competitors.

Latest Lixte Biotechnology's Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Lixte Biotechnology Holdings over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Lixte Biotechnology's Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0.22 X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Lixte Book Value Per Share Regression Statistics

	Arithmetic Mean	3.74
	Coefficient Of Variation	217.45
	Mean Deviation	4.01
	Median	2.09
	Standard Deviation	8.14
	Sample Variance	66.23
	Range	32.6497
	R-Value	0.42
	Mean Square Error	58.88
	R-Squared	0.17
	Significance	0.12
	Slope	0.76
	Total Sum of Squares	927.20

Lixte Book Value Per Share History

	2024	2.27
	2023	2.09
	2022	32.65
	2021	3.56
	2020	4.44
	2019	2.18
	2018	4.21

Other Fundumenentals of Lixte Biotechnology

Tangible Book Value Per Share

Lixte Biotechnology Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Short Term Debt	Net Receivables	Current Deferred Revenue	Net Tangible Assets	Net Invested Capital	Net Working Capital	Deferred Long Term Liab	Capital Stock
Total Assets		0.96	-0.97	-0.76	0.24	1.0	-0.3	0.46	0.91	-0.66	0.35	0.58	0.95	0.94	-0.11	0.01
Total Stockholder Equity	0.96		-1.0	-0.84	0.21	0.96	-0.4	0.42	0.88	-0.71	0.34	0.64	0.98	0.98	-0.35	-0.27
Net Debt	-0.97	-1.0		0.83	-0.22	-0.97	0.38	-0.43	-0.89	0.72	-0.34	-0.63	-0.97	-0.97	0.32	0.23
Retained Earnings	-0.76	-0.84	0.83		-0.45	-0.75	0.38	-0.51	-0.72	0.71	-0.69	-0.41	-0.81	-0.82	0.59	0.43
Total Liab	0.24	0.21	-0.22	-0.45		0.24	0.13	0.66	0.25	-0.01	0.48	0.04	0.16	0.17	-0.12	-0.06
Total Current Assets	1.0	0.96	-0.97	-0.75	0.24		-0.29	0.46	0.91	-0.66	0.34	0.58	0.95	0.94	-0.1	0.01
Common Stock	-0.3	-0.4	0.38	0.38	0.13	-0.29		0.16	-0.45	0.18	-0.21	-0.66	-0.45	-0.46	0.51	0.38
Accounts Payable	0.46	0.42	-0.43	-0.51	0.66	0.46	0.16		0.29	-0.54	0.29	-0.13	0.41	0.4	0.0	-0.02
Short Term Debt	0.91	0.88	-0.89	-0.72	0.25	0.91	-0.45	0.29		-0.53	0.47	0.66	0.9	0.89	-0.18	-0.04
Net Receivables	-0.66	-0.71	0.72	0.71	-0.01	-0.66	0.18	-0.54	-0.53		-0.3	-0.05	-0.7	-0.7	0.3	0.22
Current Deferred Revenue	0.35	0.34	-0.34	-0.69	0.48	0.34	-0.21	0.29	0.47	-0.3		0.06	0.35	0.35	-0.3	-0.09
Net Tangible Assets	0.58	0.64	-0.63	-0.41	0.04	0.58	-0.66	-0.13	0.66	-0.05	0.06		0.66	0.67	-0.38	-0.29
Net Invested Capital	0.95	0.98	-0.97	-0.81	0.16	0.95	-0.45	0.41	0.9	-0.7	0.35	0.66		1.0	-0.3	-0.22
Net Working Capital	0.94	0.98	-0.97	-0.82	0.17	0.94	-0.46	0.4	0.89	-0.7	0.35	0.67	1.0		-0.34	-0.27
Deferred Long Term Liab	-0.11	-0.35	0.32	0.59	-0.12	-0.1	0.51	0.0	-0.18	0.3	-0.3	-0.38	-0.3	-0.34		0.89
Capital Stock	0.01	-0.27	0.23	0.43	-0.06	0.01	0.38	-0.02	-0.04	0.22	-0.09	-0.29	-0.22	-0.27	0.89

Click cells to compare fundamentals

About Lixte Biotechnology Financial Statements

Lixte Biotechnology shareholders use historical fundamental indicators, such as Book Value Per Share, to determine how well the company is positioned to perform in the future. Although Lixte Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Lixte Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Lixte Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Book Value Per Share	2.09	2.27
Tangible Book Value Per Share	2.09	2.27

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC